A strategy that combines gene therapy with blood stem cell therapy may be a useful tool for treating a fatal brain disease, French researchers have found. These findings appear in the 6 November 2009 issue of the journal Science, which is published by AAAS, the nonprofit science society.
In a pilot study of two patients monitored for two years, an international team of researchers slowed the onset of the debilitating brain disease X-linked adrenoleukodystrophy (ALD) using a lentiviral vector to introduce a therapeutic gene into patient's blood cells. Although studies with larger cohorts of patients are needed, these results suggest that gene therapy with lentiviral vectors, which are derived from disabled versions of human immunodeficiency virus (HIV), could potentially become instrumental in treating a broad range of human disorders.
"This is the first time we were able to successfully use an HIV-derived lentivirus vector for gene therapy in humans, and also the first time that a very severe brain disease has been treated with efficacy by gene therapy. We've demonstrated that this HIV-derived lentivirus vector works as was hoped for so many years," said coauthor Patrick Aubourg, professor of pediatrics at University Paris-Descartes and head of a research unit at Inserm-University Paris Descartes.
Featured in the movie "Lorenzo's Oil," ALD is a severe hereditary condition caused by a deficiency of a protein called ALD that is involved in fatty acid degradation. Sufferers steadily lose their myelin sheath, the protective layer that coats nerve fibers in the brain. Without myelin the nerves lose function, leading to increasing physical and mental disability in patients. X-linked ALD, the most common form of the disease, affects boys starting at age 6-8 years of age and death usually occurs before the patients reach adolescence.
Bone marrow transplants typically slow progression of the disease because the donor marrow includes cells that develop into myelin-producing cells. However, finding a matching bone marrow donor can be a challenging and lengthy process, and the procedure carries considerable risks.
Genetically correcting the blood stem cells in the patients' own bone marrow may prove to be a valuable alternative approach when no matched donors are available.
In most gene therapy studies, a working gene is inserted into the genome to replace a dysfunctional, disease-causing gene. A carrier molecule called a vector is used to deliver the therapeutic gene into the patient's cells. Vectors are typically the backbones of viruses that have been genetically altered to carry normal human DNA. Scientists have recently turned to vectors based on the lentivirus genus of retroviruses, which includes HIV. Lentiviral vectors are a type of retrovirus that can infect both dividing and nondividing cells, and are thought to provide long-term and stable gene expression, unlike other retroviruses.
"The HIV-derived lentivirus vector allows expression of the therapeutic gene in principle for life, because the therapeutic gene is inserted in the chromosomes--the genome. Therefore, cells that derive from the initially corrected cells, stem cells in particular, will continue to express the therapeutic gene forever," said Aubourg.
In the study, blood stem cells were removed from the patients and genetically corrected in the lab, using a lentiviral vector to introduce a working copy of the ALD gene into the cells. The modified cells were then infused back into the patients' after they had received a treatment that destroyed their bone marrow. Two years later, healthy ALD proteins were still detectable in both patients' blood cells. Encouragingly, both patients showed neurological improvement and a delay in disease progression comparable to that seen with bone marrow transplants.
The healthy ALD protein was expressed in about 15 percent of blood cells, yet surprisingly this low level was sufficient to slow brain disease in ALD. "This percentage of correction will not be sufficient for all diseases," warns Aubourg. "There is a lot of work to be done to make this gene therapy vector more powerful, less complicated, and less expensive. This is only the beginning," he said.
Gene therapy is not without serious risks. Like other retrovirus vectors, the HIV-derived lentivirus vector is tasked with inserting the therapeutic gene in the chromosomes of the patients' cells. In a worst case scenario, this action could disturb the biology of the cells and patients could end up with leukemia; this outcome has occurred in past gene therapy trials. "The HIV-derived lentivirus vector basically has this same risk, although the design of the vector makes patients less prone to this side effect," said Aubourg.
This research was funded by INSERM (National Institute of Health and Research Medical), Assistance Publique des Hôpitaux de Paris, PHRC programs, the Deutsche Forchungsgemeinschaft and the German Ministry of Education and Research, the European Leukodystrophy Association, the Association Française contre les Myopathies, the Stop ALD Foundation and University Paris-Descartes.Related Press Briefing in France: A press conference related to the forthcoming Science paper, "Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-linked Adrenoleukodystrophy," by Dr. Nathalie Cartier and colleagues is planned for 2:00 p.m. in Paris on Wednesday, 4 November.
All information released during the press conference will remain under embargo until 2:00 p.m. U.S. ET/8:00 p.m. CET Thursday, 5 November 2009.
Speakers include Drs. Nathalie Cartier and Patrick Aubourg from l'Institut National de la Santé et de la recherche médicale (INSERM) and the Hopital Saint-Vincent de Paul in Paris, France, Dr. Christof von Kalle from the National Center for Tumor Diseases and German Cancer Research Center in Heidelberg, Germany, and Dr. Salima Hacein-Bey-Abina from Hôpital Necker Enfants-Malades in Paris, France who will present at INSERM, Meeting Room 132 (10th floor) 101 rue de Tolbiac, Paris 13ème (Web site: http://www.
The embargoed press briefing, for journalists only, is being organized by the journal Science and its publisher, the nonprofit American Association for the Advancement of Science (AAAS), in cooperation with INSERM.
Reporters interested in attending the briefing are asked to send an e-mail to firstname.lastname@example.org requesting pre-registration, or to request materials, please contact Natasha Pinol, senior communications officer, at email email@example.com.
An audio file will be available on the Science Press Package website at www.eurekalert.org/jrnls/sci/ (please enter your username and passcode).
The American Association for the Advancement of Science (AAAS) is the world's largest general scientific society and publisher of the journal, Science (www.sciencemag.org), Science Signaling (www.sciencesignaling.org), and Science Translational Medicine (www.sciencetranslationalmedicine.org). AAAS was founded in 1848, and serves 262 affiliated societies and academies of science, reaching 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million. The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to "advance science and serve society" through initiatives in science policy; international programs; science education; and more. For the latest research news, log onto EurekAlert!, www.eurekalert.org, the premier science-news Web site, a service of AAAS.